ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy Aging

NCT07871799 on ClinicalTrials.gov · last registry update 2026-10-13

A small phase 2 — 31 participants, against a typical 110. The sponsor logged completion for 25 February 2026. Primary outcome, as filed: Change From Baseline in Muscular-Immune-Cognitive Composite (MIC-C) Score at Week 8. The registry entry has been edited 1 time since then.

Status: COMPLETED
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Sheba Medical Center
Sponsor type: Other Gov
Enrollment: 31
Started: 2025-11-17
Primary completion: 2026-02-25 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Detected	Change	Detail
2026-10-13	First seen in registry	Registered as COMPLETED, P2

Primary outcome

Change From Baseline in Muscular-Immune-Cognitive Composite (MIC-C) Score at Week 8

Conditions studied

Healthy Aging

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.